JP2005506285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506285A5 JP2005506285A5 JP2002567353A JP2002567353A JP2005506285A5 JP 2005506285 A5 JP2005506285 A5 JP 2005506285A5 JP 2002567353 A JP2002567353 A JP 2002567353A JP 2002567353 A JP2002567353 A JP 2002567353A JP 2005506285 A5 JP2005506285 A5 JP 2005506285A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- retinoid
- retinoic acid
- use according
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 12
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 12
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 12
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims 10
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims 10
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 10
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims 10
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 10
- 150000004492 retinoid derivatives Chemical class 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 229930002330 retinoic acid Natural products 0.000 claims 6
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims 5
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims 5
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 claims 5
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 claims 5
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 claims 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 5
- 235000007240 daidzein Nutrition 0.000 claims 5
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 5
- 235000019126 equol Nutrition 0.000 claims 5
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims 5
- 235000006539 genistein Nutrition 0.000 claims 5
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 5
- 229940045109 genistein Drugs 0.000 claims 5
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims 5
- 235000008777 kaempferol Nutrition 0.000 claims 5
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims 5
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 claims 5
- 235000005875 quercetin Nutrition 0.000 claims 5
- 229960001285 quercetin Drugs 0.000 claims 5
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 5
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 5
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 4
- -1 lavendastine Chemical compound 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 229960001727 tretinoin Drugs 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 229940121647 egfr inhibitor Drugs 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 2
- 208000001126 Keratosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010039580 Scar Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 229960001445 alitretinoin Drugs 0.000 claims 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000002981 blocking agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002113 chemopreventative effect Effects 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004299 exfoliation Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229960005280 isotretinoin Drugs 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000019612 pigmentation Effects 0.000 claims 2
- 239000011604 retinal Substances 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims 2
- 229960003471 retinol Drugs 0.000 claims 2
- 235000020944 retinol Nutrition 0.000 claims 2
- 239000011607 retinol Substances 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000000475 sunscreen effect Effects 0.000 claims 2
- 239000000516 sunscreening agent Substances 0.000 claims 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 1
- 239000012459 cleaning agent Substances 0.000 claims 1
- 230000032798 delamination Effects 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 239000000344 soap Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27189401P | 2001-02-27 | 2001-02-27 | |
| PCT/US2002/006175 WO2002067988A2 (en) | 2001-02-27 | 2002-02-27 | Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008216055A Division JP2009079038A (ja) | 2001-02-27 | 2008-08-26 | 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然ｅｇｆｒ阻害剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506285A JP2005506285A (ja) | 2005-03-03 |
| JP2005506285A5 true JP2005506285A5 (enExample) | 2005-06-30 |
Family
ID=23037535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567353A Pending JP2005506285A (ja) | 2001-02-27 | 2002-02-27 | 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然ｅｇｆｒ阻害剤の使用 |
| JP2008216055A Pending JP2009079038A (ja) | 2001-02-27 | 2008-08-26 | 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然ｅｇｆｒ阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008216055A Pending JP2009079038A (ja) | 2001-02-27 | 2008-08-26 | 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然ｅｇｆｒ阻害剤の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6638543B2 (enExample) |
| EP (1) | EP1370294A2 (enExample) |
| JP (2) | JP2005506285A (enExample) |
| AU (1) | AU2002255627B2 (enExample) |
| BR (1) | BR0207663A (enExample) |
| CA (1) | CA2439408C (enExample) |
| MX (1) | MXPA03007609A (enExample) |
| WO (1) | WO2002067988A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039026B1 (en) | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
| US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
| US8093293B2 (en) | 1998-07-06 | 2012-01-10 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin conditions |
| US20040047828A1 (en) * | 1998-08-01 | 2004-03-11 | Merck Patent Gmbh | Ectoin or ection derivatives and surfactants |
| US7144880B2 (en) | 1999-04-30 | 2006-12-05 | Regents Of The University Of Michigan | Compositions relating to novel compounds and targets thereof |
| US20060025388A1 (en) * | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
| US7985404B1 (en) | 1999-07-27 | 2011-07-26 | Johnson & Johnson Consumer Companies, Inc. | Reducing hair growth, hair follicle and hair shaft size and hair pigmentation |
| US7309688B2 (en) | 2000-10-27 | 2007-12-18 | Johnson & Johnson Consumer Companies | Topical anti-cancer compositions and methods of use thereof |
| US7048910B2 (en) | 2000-09-07 | 2006-05-23 | Merck Patent Gmbh | Use of ectoine or ectoine derivatives for oral care |
| US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
| US7192615B2 (en) | 2001-02-28 | 2007-03-20 | J&J Consumer Companies, Inc. | Compositions containing legume products |
| KR100358819B1 (ko) * | 2001-06-12 | 2002-10-25 | 김기홍 | 생약 패취제 |
| DE10214257A1 (de) * | 2002-03-28 | 2003-10-16 | Merck Patent Gmbh | Verwendung von kompatiblen Soluten zur Inhibierung der Freisetzung von Ceramiden |
| US20060122262A1 (en) | 2002-10-29 | 2006-06-08 | Lephart Edwin D | Use of equol for treating androgen mediated diseases |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| US9173866B2 (en) * | 2002-07-24 | 2015-11-03 | Children's Hospital Medical Center | Compositions and products containing R-equol, and methods for their making |
| WO2004022024A1 (en) * | 2002-09-07 | 2004-03-18 | Johnson & Johnson Consumer France S.A.S. | Compositions comprising soy products and organic salts of certain metals |
| CZ2005181A3 (cs) * | 2002-09-23 | 2005-08-17 | Novogen Research Pty Ltd | Léčba stárnutí pokožky vlivem světla a aktinického poškození pokožky |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| US7498127B2 (en) * | 2002-12-20 | 2009-03-03 | Shigeki Higashiyama | Method of screening cell growth inhibitor and cell growth inhibitor |
| AU2004253579B2 (en) * | 2003-07-01 | 2010-12-23 | Biomol International L.P. | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US20050171027A1 (en) * | 2003-12-29 | 2005-08-04 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| CA2564399A1 (en) * | 2004-04-28 | 2005-11-17 | Brigham Young University | Use of equol for treating skin diseases |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| CA2580329C (en) | 2004-09-13 | 2015-01-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
| WO2006074358A1 (en) | 2005-01-03 | 2006-07-13 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US20070042026A1 (en) * | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| CA2610854A1 (en) * | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| WO2006127905A2 (en) | 2005-05-24 | 2006-11-30 | Chrono Therapeutics, Inc. | Portable drug delivery device |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| FR2894821B1 (fr) * | 2005-12-15 | 2008-02-29 | Galderma Res & Dev | Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations |
| JP5023323B2 (ja) * | 2006-06-13 | 2012-09-12 | 国立大学法人 熊本大学 | アクアポリン５の発現亢進剤 |
| JP2010504974A (ja) * | 2006-09-28 | 2010-02-18 | フォリカ，インコーポレーテッド | 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物 |
| US20080118449A1 (en) * | 2006-11-21 | 2008-05-22 | Alvin Ronlan | Cosmetic formulations of piceatannol and retinoids and methods of use thereof |
| JP5746807B2 (ja) | 2006-12-28 | 2015-07-08 | アルロン・ジャパン株式会社 | 皮膚用化粧品の組成物 |
| EP2120917B1 (en) * | 2007-02-28 | 2014-01-22 | University Of Kentucky Research Foundation | Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy |
| WO2009005815A1 (en) * | 2007-07-05 | 2009-01-08 | Enhanced Pharmaceuticals, Inc. | Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs |
| AU2010212513B2 (en) * | 2009-10-02 | 2016-08-25 | Monash University | Ectopic pregnancy treatment |
| US9126978B2 (en) | 2009-11-17 | 2015-09-08 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
| CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
| WO2016145373A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
| EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| MX2021007678A (es) * | 2018-12-25 | 2021-08-24 | Sol Gel Tech Ltd | Tratamiento de trastornos de la piel con composiciones que comprenden un inhibidor de egfr. |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| CN114206315A (zh) * | 2019-07-24 | 2022-03-18 | 索尔-格尔科技有限公司 | 用局部他匹那洛夫-egfr抑制剂组合物治疗皮肤病 |
| KR20220097429A (ko) * | 2019-11-06 | 2022-07-07 | 솔-겔 테크놀로지스 리미티드 | 손발바닥각피증 치료 방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2124059A (en) | 1982-07-09 | 1984-02-08 | Gen Electric Co Plc | Signal distribution networks |
| JPH06312919A (ja) * | 1993-05-06 | 1994-11-08 | Kao Corp | 美白剤及びこれを含有する皮膚化粧料 |
| DE4444238A1 (de) | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
| WO1998014431A1 (en) * | 1996-10-01 | 1998-04-09 | Kyowa Hakko Kogyo Co., Ltd. | Nitrogenous heterocyclic compounds |
| US5824702A (en) | 1996-06-07 | 1998-10-20 | Mount Sinai School Of Medicine Of The City University Of New York | Genistein as a preventive against ultraviolet induced skin photodamage and cancer |
| PL188574B1 (pl) | 1996-09-27 | 2005-02-28 | Unilever Nv | Kompozycja do pielęgnacji skóry |
| US5665367A (en) * | 1996-09-27 | 1997-09-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing naringenin and/or quercetin and a retinoid |
| DE19713092A1 (de) * | 1997-03-27 | 1998-10-01 | Wacker Chemie Gmbh | Komplexe aus Gamma-Cyclodextrin und Retinol bzw. Retinol-Derivaten sowie Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
| FR2782919B1 (fr) * | 1998-09-04 | 2001-05-25 | Roc Sa | Composition contre le vieillissement et son utilisation |
| KR100332031B1 (ko) | 1999-06-03 | 2002-04-10 | 서경배 | 피부 주름의 개선 및 생성 억제 효과를 갖는 외용제 조성물 |
| IL151299A0 (en) * | 2000-02-16 | 2003-04-10 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
-
2002
- 2002-02-27 MX MXPA03007609A patent/MXPA03007609A/es active IP Right Grant
- 2002-02-27 BR BR0207663-2A patent/BR0207663A/pt not_active Application Discontinuation
- 2002-02-27 WO PCT/US2002/006175 patent/WO2002067988A2/en not_active Ceased
- 2002-02-27 JP JP2002567353A patent/JP2005506285A/ja active Pending
- 2002-02-27 EP EP02725038A patent/EP1370294A2/en not_active Withdrawn
- 2002-02-27 AU AU2002255627A patent/AU2002255627B2/en not_active Expired
- 2002-02-27 CA CA2439408A patent/CA2439408C/en not_active Expired - Lifetime
- 2002-02-27 US US10/085,978 patent/US6638543B2/en not_active Expired - Lifetime
-
2003
- 2003-08-12 US US10/639,160 patent/US20040033207A1/en not_active Abandoned
-
2008
- 2008-08-26 JP JP2008216055A patent/JP2009079038A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506285A5 (enExample) | ||
| US9782334B2 (en) | Systems and methods for skin rejuvenation | |
| CA2439408A1 (en) | Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor | |
| Araviiskaia et al. | Dermocosmetics: beneficial adjuncts in the treatment of acne vulgaris | |
| Rendon et al. | Review of skin‐lightening agents | |
| US5703122A (en) | Ascorbic acid compositions for reducing irritation of topically applied active ingredients | |
| Glaser | Anti-aging products and cosmeceuticals | |
| Reszko et al. | Cosmeceuticals: practical applications | |
| US20020127256A1 (en) | Compositions and methods for treating dermatological disorders | |
| US20070269537A1 (en) | Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System | |
| US8232417B1 (en) | Artemisinin derivatives with natural amino acids, peptides, and amino sugars for skin imperfections and infection in mammals | |
| JP2006505583A5 (enExample) | ||
| US8911774B2 (en) | Topical composition for anti-aging skin treatment using dual DNA repair mechanism and method of use | |
| WO2008028636A1 (en) | Skin care composition | |
| US8193376B2 (en) | Artemisinin derivatives with natural amino acids, peptides, and amino sugars for the treatment of infection and topical condition in mammals | |
| Draelos | Cosmeceuticals for rosacea | |
| KR20010089781A (ko) | 콩을 이용한 탈색 및 피부 보호 조성물 | |
| Bellad et al. | Development ofcosmeceuticals | |
| US9968546B2 (en) | Topical composition for skin treatment to reduce lines and wrinkles of the face and body using a dual DNA repair mechanism to address damage caused by aging and ultra-violet induced damage to the skin with combination of skin turgor enhancement compounds | |
| US8394851B2 (en) | Osmoprotective complexes for prevention of mitochondrial free radical damage related skin aging | |
| US8314070B2 (en) | Osmoprotective complexes for prevention of intra-cellular dehydration in mammals | |
| EP1694337A2 (en) | Topical use of halosalicylic acid derivatives | |
| JP2008533112A (ja) | 特に酒さの治療のためのアベルメクチンとアゼライン酸に基づく組成物 | |
| JP2008534524A5 (enExample) | ||
| Chudzinska | Does bakuchiol deserve to be called plant-based retinol? Advantages and disadvantages of bakuchiol and retinol |